2. Search Result
Search Result
Results for "

arterial hypertrophy

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0592
    Trandolapril

    RU44570

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
    Trandolapril
  • HY-W414915
    Valsartan methyl ester

    CGP 48933 methyl ester

    		 Drug Derivative Angiotensin Receptor Cardiovascular Disease Cancer
    Valsartan (CGP 48933) methyl ester is the methyl ester derivative of Valsartan (HY-18204). Valsartan is a selective and orally active angiotensin II type 1 (AT1) receptor blocker (ARB) with potent antihypertensive and cardioprotective effects. Valsartan competitively binds to AT1 receptors, inhibiting the binding of angiotensin II to AT1 receptors, thereby blocking angiotensin II-mediated vasoconstriction, sodium retention, and myocardial hypertrophy signaling pathways. Valsartan reduces systolic blood pressure in L-NAME-induced hypertensive rats. Valsartan can be used for the study and treatment of arterial hypertension, hypertensive heart disease, and heart failure .
    Valsartan methyl ester
  • HY-119081
    GSK2181236A

    		Guanylate Cyclase Cardiovascular Disease
    GSK2181236A is a NO-insensitive soluble guanylate cyclase (sGC) activator. GSK2181236A can dilate blood vessels, decrease mean arterial pressure and attenuate the development of cardiac hypertrophy. GSK2181236A can be used for the research of cardiovascular disease, such as hypertension .
    GSK2181236A
  • HY-115477
    Brilaroxazine hydrochloride

    RP5063 hydrochloride

    		 5-HT Receptor Cardiovascular Disease
    Brilaroxazine (RP5063) hydrochloride is a modulator of serotonin receptors, exhibiting potential therapeutic activity in the treatment of pulmonary arterial hypertension (PAH). Brilaroxazine hydrochloride has been shown to limit functional and structural changes associated with PAH, leading to significant improvements in pulmonary hemodynamics and right ventricular hypertrophy. Brilaroxazine hydrochloride also enhances oxygen saturation levels and alleviates elevated pulmonary arterial pressures when used as an adjunct to standard PAH therapies.
    Brilaroxazine hydrochloride
  • HY-W414915R
    Valsartan methyl ester (Standard)

    CGP 48933 methyl ester (Standard)

    		 Reference Standards Drug Derivative Angiotensin Receptor Cardiovascular Disease
    Valsartan (CGP 48933) methyl ester (Standard) is the analytical standard of Valsartan methyl ester (HY-W414915). This product is intended for research and analytical applications. Valsartan methyl ester is the methyl ester derivative of Valsartan (HY-18204). Valsartan is a selective angiotensin II type 1 (AT1) receptor blocker (ARB) with potent antihypertensive and cardioprotective effects. Valsartan competitively binds to AT1 receptors, inhibiting the binding of angiotensin II to AT1 receptors, thereby blocking angiotensin II-mediated vasoconstriction, sodium retention, and myocardial hypertrophy signaling pathways. Valsartan reduces systolic blood pressure in L-NAME-induced hypertensive rats. Valsartan can be used for the study and treatment of arterial hypertension, hypertensive heart disease, and heart failure .
    Valsartan methyl ester (Standard)
  • HY-B0592R
    Trandolapril (Standard)

    RU44570 (Standard)

    		 Reference Standards Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Trandolapril (Standard) is the analytical standard of Trandolapril. This product is intended for research and analytical applications. Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
    Trandolapril (Standard)
  • HY-B0592A
    Trandolapril hydrochloride

    RU44570 hydrochloride

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Trandolapril (RU44570) hydrochloride is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolapril hydrochlorideat. Trandolapril hydrochloride is an orally active angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
    Trandolapril hydrochloride
  • HY-103084
    PDE5-IN-1

    		Phosphodiesterase (PDE) Cardiovascular Disease
    PDE5-IN-1 is an orally active, selective PDE5 inhibitor with an IC50 of 5.6 nM. PDE5-IN-1 forms hydrogen bond interactions with the Q817 residue in the catalytic domain of PDE5, and aromatic π-π stacking interactions with the F820 residue. PDE5-IN-1 exerts anti-cardiac hypertrophy and vasodilatory effects, reduces mean pulmonary arterial pressure and right ventricular hypertrophy index. PDE5-IN-1 can be used in the research of pulmonary arterial hypertension .
    PDE5-IN-1
  • HY-183644
    LNO 9

    		Lysyl Oxidase Cardiovascular Disease
    LNO 9 is an orally active LOXL2 inhibitor and NO donor, with an IC50 of 0.17 μM against human LOXL2. LNO 9 competitively binds to the LTQ cofactor of LOXL2 to form an irreversible complex, thereby inhibiting collagen oxidation and abnormal cross-linking. LNO 9 releases nitric oxide (NO) to increase cGMP levels in pulmonary artery smooth muscle cells. LNO 9 inhibits hypoxia-induced collagen modification and possesses vasodilatory activity. LNO 9 ameliorates right ventricular hypertrophy and pulmonary artery medial thickness in rat models induced by hypoxia and Monocrotaline (HY-N0750), and can be used for research on pulmonary hypertension .
    LNO 9

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: